Effect of Cilostazol on Endothelial Progenitor Cells and Endothelial Function in High Risk for Cardiovascular Disease
Status:
Completed
Trial end date:
2014-08-01
Target enrollment:
Participant gender:
Summary
1. The number and function of circulating endothelial progenitor cells (EPCs) are inversely
associated with coronary risk factors and atherosclerotic diseases.
2. This double-blind, randomized, placebo-controlled trial to evaluate the effects of
cilostazol on human early EPCs and endothelial function as well as the potential
mechanisms of action in patients with high risk for cardiovascular disease.
Phase:
Phase 4
Details
Lead Sponsor:
National Cheng-Kung University Hospital
Collaborator:
Department of Health, Executive Yuan, R.O.C. (Taiwan)